title: Estimation of atorvastatin calcium and fenofibrate in tablets by derivative spectrophotometry and liquid chromatography.
abstract: Two simple and accurate methods to determine atorvastatin calcium (ATO) and fenofibrate (FEN) in combined dosage forms were developed using second-derivative spectrophotometry and reversed-phase liquid chromatography (LC). ATO and FEN in combined preparations (tablets) were quantitated using the second-derivative responses at 245.64 nm for ATO and 289.56 nm for FEN in spectra of their solution in methanol. The calibration curves were linear [correlation coefficient (r) = 0.9992 for ATO and 0.9995 for FEN] in the concentration range of 3-15 microg/mL for ATO and FEN. In the LC method, analysis was performed on a Hypersil ODS-C18 column (250 mm x 4.6 mm id, 5 microm particle size) in the isocratic mode using the mobile phase methanol-water (90 + 10, v/v), adjusted to pH 5.5 with orthophosphoric acid, at a flow rate of 1 mL/min. Measurement was made at a wavelength of 246.72 nm. Both drugs were well resolved on the stationary phase, and the retention times were 1.95 min for ATO and 5.50 min for FEN. The calibration curves were linear (r = 0.9985 for ATO and 0.9976 for FEN) in the concentration range of 3-15 microg/mL for ATO and FEN. Both methods were validated, and the results were compared statistically. They were found to be accurate, precise, and specific. The methods were successfully applied to the estimation of ATO and FEN in combined tablet formulations.
authors.affiliation: A.R. College of Pharmacy, Vallabh Vidyanager - 388120, Dist. Anand, Gujarat, India. nvnakarani_mpharm@yahoo.co.in
authors.forename: Naresh V
authors.initials: NV
authors.lastname: Nakarani
authors.forename: Kashyap K
authors.initials: KK
authors.lastname: Bhatt
authors.forename: Rutva D
authors.initials: RD
authors.lastname: Patel
authors.forename: Hemaxi S
authors.initials: HS
authors.lastname: Bhatt
mesh_terms: D000924:Anticholesteremic Agents / Q000032:analysis; D000069059:Atorvastatin; D002138:Calibration; D002626:Chemistry, Pharmaceutical / Q000295:instrumentation / Q000379:methods*; D002853:Chromatography, Liquid / Q000379:methods; D004304:Dosage Forms; D011345:Fenofibrate / Q000032:analysis* / Q000737:chemistry; D006538:Heptanoic Acids / Q000032:analysis* / Q000737:chemistry; D006863:Hydrogen-Ion Concentration; D000960:Hypolipidemic Agents / Q000032:analysis; D008956:Models, Chemical; D011758:Pyrroles / Q000032:analysis* / Q000737:chemistry; D012044:Regression Analysis; D015203:Reproducibility of Results; D013053:Spectrophotometry; D013056:Spectrophotometry, Ultraviolet; D013607:Tablets
chemical_list: D000924:Anticholesteremic Agents; D004304:Dosage Forms; D006538:Heptanoic Acids; D000960:Hypolipidemic Agents; D011758:Pyrroles; D013607:Tablets; D000069059:Atorvastatin; D011345:Fenofibrate